

WELCOME TO THE WELCOME

For the third Research & Innovations Symposium, HSL have continued their excellent relationship with the Wellcome Collection as the venue. It is an institution steeped in science and medicine history and boasts a World-class array of exhibits and displays.

The venue is overseen by the Wellcome Trust who also run the Wellcome Library which is home to more than 750,000 books and journals as well as an extensive range of manuscripts, archives and films.

HSL are extremely grateful to the Wellcome Collection for their support and we hope that all delegates and sponsors enjoy their visit to the venue.

About the Trust

Sir Henry Wellcome (1853-1936), the founder of the Wellcome Trust, was one of the most fascinating men of his time. A businessman, collector and philanthropist, he was born in the American Wild West but ended his days as a knight of the British Realm. Wellcome co-founded a multinational pharmaceutical company that mastered modern techniques of advertising such as promotion, image and branding.

The wealth that Wellcome's company brought him was invested in amassing an astonishing collection of historical objects, which at the time of his death was larger than that of many of Europe's most famous museums. He also funded pioneering medical research. In his lifetime, scientists funded by Wellcome made great breakthroughs into understanding how our bodies work. After his death, Wellcome's will provided for the creation of the Wellcome Trust. Today, the Wellcome Trust is a champion of science, funding research and influencing health policy across the globe.

The Trust's Philosophy

Good health makes life better. We want to improve health for everyone by helping great ideas to thrive. Science and research expand knowledge by testing and investigating ideas. This new understanding can be applied to health and change medicine, behaviour and society.

That's why we support thousands of curious, passionate people all over the world to explore great ideas, at every step of the way from discovery to impact. Together, we can do more. We can drive reform to ensure that ideas can reach their full potential. And we can give focused, intensive support when we see real opportunities to transform lives. As an independent charitable foundation, we're willing to take risks. We combine the ability to act swiftly with long-term ambition.

That's how we make life better.



The human genome library on display at Wellcome Collection



"Medicine Man" exhibit at Wellcome Collection



Date: 7th November 2017

Dear Delegates,

I would like to welcome you to our 3rd Annual HSL Research and Innovations Symposium.

It has been a very busy year for everyone involved in moving into the new labs at the Halo Building but we are almost there. The completed laboratory is now one of the largest in the UK and has drawn much favourable comment from visitors. The next stage will involve the refurbishment of 60 Whitfield Street as a Rapid Response Lab for UCLH and to bring together our histopathologists in a purposely designed centre.

The infrastructure to support translational research is now well established and the success of this is well demonstrated by the approaching 500 research projects and clinical trials we have in the research portfolio with UCL and its partners. We have also made contact with the Crick Institute and this partnership is likely to flourish in the future as they will have strong portfolio of basic research and will be looking for clinical links to translate it into improvements in patient care. HSL and its partners are in a good position to bring new diagnostics into clinical practice and we are likely to see this in the foreseeable future in areas such as cell free diagnosis and companion diagnostics for cancer.

We have an excellent program of speakers on cancer and infectious disease in the morning and following the feedback from last year's symposium we have put in a session of training and highlighted some of the new projects going on in the labs in the afternoon sessions. We hope you will enjoy the programme.

Please complete the CPD feedback forms and leave them on the admissions desk at the close of the meeting. We value your feedback and it is also essential to continuing to have formal CPD accreditation.

Yours Sincerely

Professor Michael Patton

Group Medical Director
HSL Pathology LLP

USEFUL EVENT INFORMATION

Thank you for attending the HSL Research & Innovations Symposium, 2017. We hope this will be an educational and enlightening day - and that you'll use the information you obtain in your daily work. Although we intend today to run in a relaxed manner, we have several polite requests to ensure the smooth running of the event.

Registration Desk

The first desk you will see when entering the "Williams Lounge" is the event registration desk. This will be manned throughout the day so please visit here to pass on any feedback or to ask a question.

CPD Points

Attending the HSL Research & Innovations Symposium will earn 5 credits for RCPATH members. Recent changes to the IBMS system means that credits are no longer awarded. However you can still use your certificate of attendance towards your IBMS CPD diploma. It is important that you complete the CPD feedback forms, which will be given to you when registering for the symposium, if you wish to obtain these points. Upon handing in your survey at the registration desk, you will receive your certificates.

Poster Competition

For 2017, HSL have asked for poster submissions by delegates and other HSL staff, to be displayed at the event. These demonstrations of the excellent work carried out by HSL staff and partners, will be judged during the lunchtime break with a prize awarded to the winner at the end of the day. Abstracts for each entry can be found next to each poster.

Venue Times

We ask all delegates to adhere to the times shown on the itinerary. The Wellcome Collection are hosting another event directly after the HSL R&I Symposium has ended. Therefore we politely ask that all delegates, and staff have vacated the venue by 5:00pm.

Timings

The HSL Research & Innovations Symposium is a very busy event. There are 13 presenters as well as various exhibits and refreshment breaks to fit in during the day. May we politely ask that delegates arrive promptly at the venue to assist us in keeping to the timings of the event, which are printed on the back of this guide.

Photography

Both HSL and the Wellcome Collection ask that no photography is taken outside of the Auditorium or the trade show area. There will be an official photographer documenting the day. Some of these images will feature in the HSL newsletter and on the HSL website. If you wish to NOT be included in any photography, please mention this at the registration desk.



Professor Judith Breuer addressing the audience at last year's HSL Research & Innovations Symposium

WHO ARE THE CHAIRS?



Prof Geoff Bellingan - *Medical Director for Surgery & Cancer Board, UCLH*

Geoff Bellingan was appointed Medical Director in September 2009. He previously held posts as Clinical Director and Divisional Clinical Director between 2006 and 2009. He trained as a chest physician and then in intensive care in which he has been a consultant at UCLH since 1997. He was appointed as a Professor in intensive care medicine at UCL in 2015. As Medical Director for Surgery and Cancer, Geoff has a particular interest in cancer care across North and East London and West Essex, working closely with London Cancer, Macmillan and a number of other major partners. This led to the successful UCLH Cancer Collaborative application and the award of the national Cancer Vanguard in partnership with Greater Manchester Cancer Vanguard Innovation and Royal Marsden Partners.



Dr Robin Smith - *Clinical Lead for Infection Sciences, HSL/RFL*

Dr Robin Smith trained in medicine at The United Medical and Dental Schools of Guy's and St Thomas'. She was drawn to microbiology as a discipline spanning all medical specialties and affecting the whole population, during a time of emerging antibiotic resistance and increasing recognition of the importance of infection prevention and control. After specialty training, she joined the Royal Free Hospital as a microbiology consultant in 2005, becoming clinical lead for Microbiology in 2014. She has specialist interests in infection prevention and control, microbiology diagnostics and sexually-transmitted infection. She is an honorary senior lecturer for UCL Medical School, involved in undergraduate medical student teaching and is module lead for a postgraduate MSc in Healthcare Associated Infection Control.



Prof. Michael Patton - *Group Medical Director HSL Pathology*

Professor Michael Patton has been involved in biomedical research throughout his career. He established the South West Thames Regional Genetic Service and the academic Department of Medical Genetics at St Georges. This department was very successful in identifying over 30 genes responsible for malformation syndromes and led the research into Noonan syndrome in the UK. He was the Dean for Innovation and Enterprise at the University between 2009 and 2012 and was responsible for the commercialisation of medical research and the establishment of two spin out companies. He was also a founder of the Birth Defects Foundation (now Newlife Charity for Disabled Children) which has raised around £40 million for research and disability equipment for children since its inception. He is currently the Medical Director for HSL.



Prof. Stephen Powis - *Medical Director & Professor of Renal Medicine, RFL*

Stephen Powis is professor of renal medicine at University College London. He joined the Royal Free Hospital in 1997 as a consultant, becoming the trust's medical director in 2006. His main clinical interest is renal transplantation. He is the chairman of the Association of UK Universities Medical Directors group and a board member of Merton Clinical Commissioning Group. He is a past non-executive director of North Middlesex University Hospital NHS Trust, including a period of eight months as acting chairman. He is a past chairman of the Joint Royal Colleges of Physicians Training Board specialty advisory committee for renal medicine and a former board member of Medical Education England. He was director of postgraduate medical and dental education for UCL Partners from 2010 to 2013. He is the chair of the HSL Innovations Board.

WHO ARE THE SPEAKERS?



David Byrne - *CEO, Health Services Laboratories*
Update on HSL Pathology @ 9:40am

David qualified as an accountant in 1987 and following many years in a corporate finance advisory role he joined the boards of a number of healthcare and engineering companies. He joined the board of The Doctors Laboratory 20 years ago as finance director and has been the chief executive for over 14 years. In 2015 he was appointed as chief executive of Health Services Laboratories and, together with its senior management team, is overseeing the creation of one of Europe's largest and most innovative clinical laboratories. David has formed and developed a number of businesses in the healthcare sector over the last 20 years and is a non-executive director of companies operating in a wide range of medical related businesses working in sectors such as clinical software, personalised medicine and biotechnology.



Mr Adam Rosenthal - *Consultant Gynaecologist, UCLH*
Future Directions in the Prevention of Cervical Cancer @ 10:00am

Adam Rosenthal PhD FRCOG is a Consultant Gynaecologist at UCLH and directs the hospital's Cervical Screening Program. He is also the Clinical Lead on the UK Familial Ovarian Cancer Screening Study and has published extensively on screening for gynaecological cancers and their molecular biology, in journals including the Lancet and the Journal of Clinical Oncology. He is co-applicant on a number of grants from Cancer Research UK, NHS Research and Development, the Eve Appeal and the BUPA Foundation. He is a medical advisor to various charities, including Ovacome and the Eve Appeal. His clinical interests are gynaecological cancers and pre-cancers, colposcopy, laparoscopic and open surgery, anal neoplasia and inherited (familial) gynaecological cancers.



Dr Chris McNamara - *Consultant Haematologist, UCLH*
Advances in the Diagnosis & Management of Lympho-Proliferative Disease @ 10:30am

Dr Christopher McNamara is a consultant haematologist at UCLH. His interest is in the diagnosis and management of lympho-proliferative disorders. He is a specialty adviser to NEQAS haematology and was clinical lead on the NICE committee that wrote the national guidelines on the diagnosis and management of lymphomas.



Prof. Paul Griffiths - *UCL Medical School, Royal Free Campus*
Why is CMV a Candidate for Elimination and then Eradication? @ 11:35am

Paul Griffiths is Professor of Virology at University College, London. He is Editor-In-Chief of Reviews in Medical Virology. His research concerns cytomegalovirus infection, where he has helped to define the natural history and pathogenesis of this infection and used this information to design randomised controlled trials of antiviral drugs and prototype vaccines. Selected relevant peer-reviewed publications are listed below:



Prof. Tim McHugh - *Professor of Medical Microbiology & Director, UCL Centre for Clinical Microbiology, Division of Infection & Immunity, UCL*
Getting More Out of TB Laboratory Diagnosis @ 12:05pm

Tim's group contributes to all stages of the TB drug development pathway with projects on evaluation of new compounds as well as supporting the laboratory aspects of clinical trials. An underlying theme is the development of biomarkers of treatment outcome, whether transcriptomic analysis of in vitro treatments or the more complex picture of monitoring outcome in patients. An important element of his work is capacity development, we provide training for laboratory scientists both on site and in London. Tim is Academic Lead for Continuing Professional Development in the UCL School of Life and Medical Sciences and in this role he is championing the use of online education to reach a global community.

WHO ARE THE SPEAKERS?



Dr Simon Edwards - *Clinical Director for Sexual Health Services, CNWL*
The Delivery of a Sexual Health Service @ 12:35pm

Simon Edwards is a Consultant Physician with over 25 years experience in Sexual Health and HIV. He is the current Clinical Director at CNWL which is one of the UK's largest providers of treatment and care for sexual health and HIV. He has published over 100 papers and was co-chair of the BHIVA national standards for HIV care and the BHIVA Opportunistic Infection treatment guidelines. He has recently taken on the role of Quality Improvement Clinical Lead at CNWL



Wendy Leversuch - *Head of Scientific Training, HSL*
Training Programmes for Scientific Staff @ 2:00pm

Wendy's career started at University of the West of England studying biomedical science, spending her 3rd year as a Trainee Medical Laboratory Scientific Officer in the haematology department at the Royal United Hospital. Once gaining registration she moved to the North Hampshire Hospital Basingstoke as a Biomedical Scientist. After completing an MSc at the University of Portsmouth she became a Senior BMS. Wendy then joined the IBMS as Deputy Head of Education and is now the Head of Scientific Training at Health Services Laboratories, her role is to administer, direct and monitor the scientific training strategy across HSL and oversee the training requirements of all Scientific staff.



Dr Keith Gomez - *Head of Medical Training, HSL*
Support for Medical Training @ 2:15pm

Dr Keith Gomez trained at St Thomas' Hospital Medical School, University of London, and graduated in 1992. After studying haematology in the North London training programme he joined the Haemostasis Research Group at the Medical Research Council in London. The primary area of research for his doctoral thesis was the development of models of tissue factor-initiated coagulation. After award of his PhD Dr Gomez took up his current post as Consultant and Honorary Senior Lecturer in Haemostasis in the Haemophilia Centre and Thrombosis Unit at the Royal Free Hospital in London. His main research interests include the genetic basis of inherited disorders of coagulation, the diagnosis and management of platelet disorders and the clinical management of the rarer factor deficiencies.



Orine Musonda - *Senior Biomedical Scientist, TDL*
Completing the Training Portfolio & Beyond @ 2:30pm

Orine is a Senior Biomedical Scientist in Clinical Chemistry at TDL's Northwick Park Hospital site. She joined The Doctors Laboratory in 2014 as a band 5 Biomedical Scientist and has since completed her IBMS specialist diploma and was able to apply for MSc sponsorship in 2016. She is currently in her final year of her MSc.



Dr Tony Madgwick - *Principal Lecturer in Cellular Pathology, University of Westminster*
Undertaking a Master's Degree Part Time @ 2:45pm

Graduating from the University of Hull and obtaining a PhD from the Royal Veterinary College University London, Tony's background covers a diverse range of biomedical applications. His experiences span agriculture, dental/oral health, physiology and cancer from both the University of London and UCL. This diverse background provided an ideal background for later roles at Westminster University, where Tony has held the posts of Director of Biomedical Sciences short courses, course leader for the MSc Cellular Pathology courses and now as Principle Lecturer and course leader for MSc Biomedical Sciences at Westminster University where he has now worked for over 15 years.

SERVICES UPDATE

Updates in Genetics & Molecular Pathology Services

As we now begin to see the formation of a consolidated HSL genetics and molecular pathology service within the Halo building we thought we would like to take the opportunity to update you on some of the service reconfigurations in this key diagnostic area.

The consolidation of twenty-one different molecular service laboratories, performing in excess of 1 million molecular tests per year, from such a diverse range of genetic and molecular pathology disciplines within the Halo building, has provided the unique challenge and opportunity to reconfigure the landscape within these services. Whilst the majority of genetic and molecular pathology services are consolidated on levels 5 and 6, there are services which by design, are devolved to other locations within the Halo building, specifically for operational and future proofing efficiencies. Examples of this include molecular blood borne viral load testing for HIV and Hepatitis which is situated on level 2, leveraging the expectation that the instrumentation performing these assays to become accessible to the GLP tracking system in the next 18-24 months. We also see hospital associated infection and faecal microbial testing residing within enteric laboratory which is part of the Infection Sciences laboratory on level 4, facilitating efficient sample handling, triage and governance within areas local to their core discipline.

Although the vast majority of laboratory operations have consolidated, the tests themselves within genetics and molecular pathology are very much discipline-specific, requiring ongoing technical, scientific and clinical governance from the contributing specialist departments and the clinical speciality leads representing HSL, TDL and our Trust partners.

We have discussed previously our recent developments in prenatal diagnosis and we see our non-invasive prenatal (NIPT) testing services go from strength to strength and are already expanding to support prenatal screening funded by the early adopters within the NHS. The experiences gained by Dr Lisa Levett and Dr Stuart Liddle and their team in establishing non-invasive prenatal testing using cell free DNA technology has laid a strong foundation for translation adoption of similar technology in other applications. We expect over the next 12 months to begin to evaluate the use of cell free DNA laboratory processes in support of cancer, a key area for our NHS partner organisations. The utility of cell free DNA testing in cancer, an application which as the core technology continues to develop, will almost certainly see its use in monitoring of actionable mutation status and supporting the direction of targeted therapeutics in oncology. This area is a key focus in our ongoing commitment to advancing diagnostics in direct support of clinical care.

Continuing with the theme of cancer we are also beginning to see the implementation and embedding of the government funded and nationally implemented 100,000 genomes project from within our cellular pathology laboratories at UCLH, Royal Free and Northwick Park. This is a challenging project which involves novel interactions and the establishment of new clinical pathways between sample collection teams in theatre, diagnostic laboratory processes, clinical supervision and academic collaboration. We expect this project to continue to grow and adapt to what is at present a very dynamic cancer diagnostic landscape.

Led by Dr Steve Hart and Dr Ellie Nacheva and supported clinically by Dr Wai-Keong Wong and colleagues at UCLH our molecular haematological malignancy services have recently advanced on two fronts, firstly through the establishment of two new diagnostic assays. The first an improved IVD assay from for the detection of BCR-ABL1, an integral target used in the diagnosis and therapeutic monitoring of chronic myeloid leukaemia (CML). In addition, the team have successfully verified the new QuanDx multiplex PCR assay for use in the simultaneous detection of 30 fusion genes with over 140 separate breakpoints associated with haematological malignancy. This assay which can be performed in less than 3 hours is a considerable enhancement to our SIHMDS service.

These PCR-based advancements complement the continued next generation sequencing programme led by Dr Ellie Nacheva for the haemato-oncology genomics service. This team continues to develop the Illumina-based myeloid sequencing service which now tests exonic regions across 15 complete genes and oncogenic hotspots across an additional 39 genes providing a comprehensive assessment of the key drivers known to be involved in myeloid malignancies in a single test.



The virology and haemoglobinopathies team discussing next generation sequencing opportunities in post PCR.

SERVICES UPDATE

In response to a recent NIHR call we have connected several elements of our infection sciences and haematological malignancy services together to develop and submit an application for funding to establish UCLH and HSL an NIHR in vitro diagnostic assessment centre. Although this bid was ultimately unsuccessful, the bid, enthusiastically led by Dr Vanya Gant (UCLH Director of Infection) and the UCLH clinical team, supported by the BRC and HSL showed considerable potential, it clearly illustrates the ambition for HSL and the Trust clinical teams to work together to formulate strong proposals for new initiatives within the diagnostic service. We have also seen great strides from Prof Peter Wilson and the UCLH environmental team with their Cognitor study. This study, which utilises routine blood culture samples from the diagnostic microbiology laboratory, has rapidly recruited patients from A&E in the investigation into improved mechanisms of sepsis management.



Slide preparation for Karyotyping in Genetics on level 6

Considerable molecular service development work has also been undertaken by our infection sciences teams within microbiology, virology and parasitology. A key area for our infection sciences services is the provision of services to support of the diagnosis of hospital associated infection (HAI) and the infection control mechanisms that follow. This does not always mean greater adoption of molecular technology, but how it is optimally utilised within the diagnostic pathway. Last year we saw front line MRSA PCR testing at UCLH being replaced with MRSA culture as the front line screen with supportive targeted molecular testing available if required. This process has illustrated the adaptability of both the laboratory and hospital-patient facing services to meet the overall needs of the clinical service. The HSL and clinical team at the Royal Free continue to support the

development of HAI services by evaluate a range of carbapenemase detection assays, tests which focus on the detection of enzyme producing by bacteria which harbour multi-drug resistance to the carbapenem range of antibiotics.

Conversely, as part of the transformation of services in the Halo building and in conjunction with clinical colleagues at our Trust partners the microbiology team are working through the technical, clinical and operational impact of introducing a new algorithm for *C. difficile* (*C.diff*) testing. A front line PCR test has been selected and has the potential to provide the most robust first line screen for the detection of *C.diff* bacteria, which is then followed up by a confirmatory enzyme immuno assay (EIA) for the detection of *C.diff* toxins A & B. A sequential dual testing algorithm approach to *C.diff* testing is recommended by Public Health England and we hope by working closely with our clinical leads and infection control teams at our hospitals this new diagnostic algorithm, together with ongoing infection control protocols can help further improve hospital infection rates.

Following the standardisation of our group chlamydia and gonorrhoea (CT/GC) PCR testing services, other recent advancements in our sexual health diagnostic services include introduction of *Trichomonas vaginalis* (TV) PCR into routine diagnostic practice on the Hologic Panther system. This is an important new target added to our molecular sexual health testing repertoire supporting the diagnosis of one of the most globally prevalent non-viral sexually transmitted diseases.

Alongside TV we have seen the completion of verifications for *Mycoplasma genitalium* (MGEN) and *Lymphogranuloma venereum* (LGV) PCR. MGEN is a pathogenic organism found in the epithelial lining of the urinary tract and is associated with a range of sexually transmitted infections and the team have been verifying performance of this target versus traditional microscopy-based methodologies.

Complementary to TV and MGEN we have seen ongoing work which will lead to the verification of LGV PCR. LGV which is associated with disease caused by invasive serotypes L1, L2, L2a or L3 of *Chlamydia trachomatis* causing infection of lymphatics and lymph nodes, has involved the establishment of material transfer agreements and assay transfer from the Public Health England (PHE) reference laboratory in Colindale to HSL. With all these assays planned for introduction in 2017, this emphasises HSL, TDL and its clinical partners as one of the most comprehensive sexual health laboratory diagnostic service providers in the UK.

One service area which we hope to mirror our success seen in sexual health testing is Mycology, the study of fungal disease, diagnosis, treatment and epidemiology. This area, often seen as a subsection of microbiology and is playing an ever more important role in patient management, in particular in two very different populations. Firstly we see the adoption of

SERVICES UPDATE


dermatophyte PCR in the diagnostic pathway used to detect the causative organism in superficial fungal infections such as *Trichophyton rubrum* and secondly we see aspergillus and pneumocystis PCR together with associated serology based assays as providing a robust algorithmic approach to patient management of potentially life-threatening invasive fungal disease. These diagnostics also support local and national anti-fungal stewardship programs in the management and use of anti-fungal agents in the treatment of fungal disease. These areas are of particular importance to our Trust partners due to their status as international centres of excellence for treatment and management of immunocompromised patients, a diverse patient grouping encompassing from pathologies ranging from viral infection through to therapeutic suppression in areas such as transplant or cancer medicine. This service establishes the HSL mycology service as a UK Clinical Mycology Network (CMN) regional laboratory, offering complete integrated fungal diagnostics service.

Moving from bacterial and fungal to viral pathogens we also now see the virology teams at UCLH followed closely by Royal Free Hospital adopt a range of Fast Track Diagnostics viral pathogen assay. The first phase of assay introduction included targets to herpes simplex virus 1, 2, *Treponema pallidum* and varicella zoster virus followed closely by the Neuro9 assay targets. An exciting area has been the continued refinement of existing in-house developed PCR assays for respiratory and gastrointestinal viral pathogens. The biomedical and clinical scientist teams at UCLH and Royal Free Hospital, with guidance from the clinical virology teams, have developed a comprehensive combined set of assays which include a greater number and more efficient multiplex series of viral targets. These tests will be rolled out on the new QuantStudio series of instrumentation on transition to the Halo building.

On the clinical virology research front HSL continues to host and support Dr Eleni Nastouli and the UCLH/UCL virology team in their investigations into mechanisms of viral resistance and pathogen epidemiology. We look forward to seeing this BRC funded activity, producing some key new clinical insights and technical developments in viral resistance sequencing and diagnosis. We have also seen the development of Panther Fusion instrumentation from Hologic, with HSL being selected as one of three sites globally to evaluate the new Aptima respiratory virus technology. This evaluation, led by Dr Paul Grant, which is a joint exercise between UCLH and the Royal Free Hospital, has the potential to offer both IVD and flexible open channel viral targets performed using random access instrumentation and has the potential to further support our clinical services during the winter months which can see large surges in seasonal respiratory virus detection. Following on and also led by the UCLH clinical virology team we have also recently seen the development of a rapid Flu/RSV service within the A&E hot lab at UCLH, supported by the haematology hot lab team this service aims to provide rapid response respiratory diagnostics in support of the acute services departments within UCLH.

Completing the infection sciences contribution to molecular service developments, the HSL parasitology team, who maintain close connections with the Hospital of Tropical Diseases and Public Health England who continue to host the UKNEQAS scheme for diagnostic parasitology from the Halo building.

As part of the parasitology transformation programme we have seen an extensive number of molecular verifications. As an international reference laboratory with access to a range of parasites not often available to the commercial sector the team have engagingly put a range of commercially available IVD assays through their paces. Although not all assays have been clinically acceptable, one area with positive outputs has been the verification of the Fast Track Diagnostics Platform for specialist faecal parasite detection of *Entamoeba histolytica*, *Cryptosporidium spp.*, and *Giardia lamblia*. This follows comprehensive evaluation and review by the laboratory and clinical team.



SERVICES UPDATE

Whilst the specialist faecal parasite referral work performed by the HTD/ HSL parasitology team continues to go from strength to strength the routine faecal pathogen detection service is undergoing a major service change at UCLH and TDL, harmonising its processes with Royal Free and North Middlesex service in adopting the Serosep enteric pathogen platform in line with service harmonisation for the Halo building. This PCR-based assay which has a user friendly setup utilising established Roche Lightcycler PCR detection will create a new frontline faecal PCR algorithm for detection of *Salmonella*, *Shigella*, *Campylobacter*, VTEC (*E.coli*) and also as part of the latest multiplex include detection of the UK acquired parasites of *Cryptosporidium* and *Giardia*. This new pathway, following algorithm guidance from HTD and Microbiology clinical leadership at will see a reduction in the number of ova, cysts and parasites microscopy tests evaluated in the routine service, off set against a UK pathogen based PCR service. Faecal culture as always remains within the microbiology test repertoire and will continue to be used in clinically focussed esoteric scenarios such as detection of *Vibrio Cholerae*, a gram negative bacterium found in undercooked seafood which can cause severe food poisoning. Traditional microscopy for exotic traveller-associated parasitic infection from all HSL and TDL partner sites will continue to receive the comprehensive microscopy screen under new operational management of the parasitology team.

Coming full circle back to genetics, our haemoglobinopathy and haemophilia genetic services from UCLH and RFL respectively, these groups having made great strides and have completed their service moves consolidating at the Halo building. Both have recently undergone UKAS inspections and have begun implemented new automated DNA extraction and PCR processes designed to improve workflow whilst maintaining or improving on clinical target specificity.

Many thanks to all the HSL, TDL and Trust scientific and clinical teams who have contributed considerably to the changes we are now seeing implemented within our molecular services and the benefit these are bringing to our end users and patients alike.

Michael Gandy
Head of R&D and HSL Scientific Officer



IMAGES FROM 2016



The reception area in full swing



Prof Atul Mehta and Prof Michael Patton taking questions



Dr Martin Forster presenting



Poster competitions Cathering Martin and Anna Vassiliou with judge Wendy Leversuch



Prof. Martin Widschwendter presenting



Symposium Organiser Prof Michael Patton gets to grips with a virtual tour of the Halo building



Rebecca Gorton and Dr Vanya Gant on stage



innovation creativity leadership compassion

AHPandHSawards.co.uk
@AHAwards

The awards aim to:

- Identify examples of good, innovative practice throughout the four countries of the UK which are evidence-based, sustainable and transferable.
- To help AHPs and healthcare scientists communicate their key role in transforming health and social care to their various audiences: colleagues, other healthcare professionals, leaders, commissioners, patients and users of services, politicians and the media.
- To develop the awards programme in reach and stature reflecting professional aspirations and political imperatives.
- To recognise and meet the expectations of the sponsoring and supporting organisations.

The programme comprises 14 awards plus the overall winner. Judges, drawn from supporting organisations, shortlist three or four entries in each category who are invited to present to the judging panels. The results are revealed at the awards lunch on 20 April. The shortlisted teams are invited and they often chose to buy additional places with family and colleagues.

Other guests include leaders of the professional bodies and membership organisations, senior people in healthcare and guests of the sponsors.

Enter the Advancing Healthcare awards now and show how you and your team deliver the best possible care.

How to enter

- Read through all our award information and make sure you enter your project in the most suitable category. Some are only open to AHPs or to healthcare scientists
- Prepare your answers to the category submission questions offline. Go to AHPandHSawards.co.uk, select **ENTER NOW**
- Give full contact details of the project team (or nominator/nominee). Please do so carefully as we will use these forms to inform you of the results of the shortlisting
- Next cut and paste your prepared answers to the questions on to the website form, keeping to the word count limits
- Thoroughly check your entry form before submission, and ask a colleague to take a look too.
- Submit your entry well in advance of the deadline
17.00 FRIDAY 19 JANUARY 2018
- Remember you can enter as many projects as you like, but a particular project can only be entered into one category
- If you have a problem with your submission, please contact the awards team by calling **0208 334 4500** or emailing rachael@chamberdunn.co.uk

Judging criteria

Entries will be assessed and scored according to the criteria set out in the entry form for each award. For most awards, the judges are looking for:

- Measurable achievements
- Expected benefits (including cost-effectiveness/value for money)
- Sustainability and transferability
- Leadership and team-working
- Making a difference to patient/client care

But some awards ask for evidence of other achievements: check carefully for the award you are interested in. Your entry submission should address each of the questions on the online form. Your responses should be text only and not exceed the stated word limit. Shortlisting judges will score your entry on the basis of evidence provided in each section alone (appendices will not be considered).



Why enter?

RECOGNITION: ...from peers and colleagues of the good practice projects you and your team have delivered, perhaps ensuring continued funding or new development opportunities.

PROMOTE GOOD PRACTICE: Let us help get your good practice ideas spread to other health and social care providers, so others can learn from your challenges and achievements. We help you reach the media, professional press and other important forums.

A PERMANENT REMINDER: Win a stylish trophy and certificate for your workplace that reminds your patients, colleagues and peers of your professional achievements. Plus we give you photographs of your team with our ceremony guests of honour and sponsors.

CELEBRATE IN STYLE: Enjoy a special celebratory lunch on 20 April 2018 for your team at a central London hotel with the opportunity to network with other talented health professionals and health care leaders. Finalists are able to purchase additional tickets to bring family, friends and colleagues along.

REVIEW YOUR WORK: Seize the opportunity to review your project, its impact on patient care and your team working; putting pen to paper will ensure better dissemination of your ideas and learning for your own professional development.

Who can enter?

At least one team member in any entry should be an allied health professional or healthcare scientist, and should be providing healthcare in any setting within the UK.

Our mission is to grow and sustain a prestigious UK-wide awards programme for allied health professionals, healthcare scientists and those who work alongside them in support roles, which reflects their contribution to high quality person-centred care and fosters awareness of their part in transforming health and social care.

We welcome entries in the following categories:

Awards open to both AHPs and healthcare scientists...



The HEE/NIHR award for Research champions

Sponsored by Health Education England and the National Institute for Health Research

This award is open to AHPs and healthcare scientists who are currently enrolled on or have recently completed an award within the HEE/NIHR Integrated Clinical Academic (ICA) programme or its predecessors. We are looking for people that can demonstrate how they are research champions – not only undertaking their own research projects but inspiring others to become involved and to increase research capacity.



The NHS Employers award for outstanding achievement by an apprentice, support worker or technician working alongside an AHP or healthcare scientist

Sponsored by NHS Employers

Open to apprentices, support workers, assistant practitioners, technicians, or others of a similar title working within an AHP or healthcare science team. We aim to recognise and encourage their contribution to improving patient outcomes by celebrating an individual or team that provide high quality, creative care which enhances the quality of life for the patient. Nominations are welcomed from the individual, their team or by a patient, service user or carer.



The Welsh Government's award for Prudent Healthcare

Reducing inappropriate variation using evidence-based practices consistently & transparently

Sponsored by the Welsh Government

Open to AHPs and healthcare scientists who are able demonstrate progress that they or their teams have made in reducing inappropriate variation using evidence-based practices. This is a cornerstone of the Prudent Healthcare agenda in Wales. The award will recognise progress that has been made either in healthcare science or therapies in addressing variation in a measurable way for the benefit of patients and the NHS.



The CDL Rising Star award

Sponsored by Chamberlain Dunn Learning

We invite you to nominate a colleague or member of staff who has shown a level of initiative, skill and commitment that is truly exceptional. You may nominate anyone who has been working as a qualified AHP or healthcare scientist for less than five years, and who you and others recognise as a star in the making.

Awards open to healthcare scientists only...

These awards are supported by the Academy for Healthcare Science.



Viapath award for innovation in healthcare science

Sponsored by Viapath

This award is about recognising and rewarding the vital contribution of science to healthcare delivery. We are looking for innovation that is sustainable, transferable and plays a demonstrable part in delivering service transformation. The judges will be looking for scientific initiatives which have delivered tangible improvements to healthcare provision. The benefits can be across a range of deliverables: the integration of services, accelerating diagnosis and treatment, the provision of greater patient control of their own care.



The Scottish Government's award for Driving improvement, delivering results

Sponsored by the Scottish Government

Open to all healthcare scientists in Scotland who have demonstrated their expertise to drive improvement and maximise the contribution of healthcare science. The ambition is to deliver sustainable and coherent teams and services that promote the overall NHS Scotland's ambitions of improving quality, safety and patient experiences of care.

7

HEALTH SERVICES
LABORATORIES

Biomedical Scientist of the Year award

Sponsored by Health Services Laboratories (HSL)

This award celebrates an exceptional biomedical scientist who has used his or her skills and expertise to advance practice in an innovative and impactful way, making a real difference to patients' lives and inspiring those around them. You may nominate yourself, a colleague, or suggest he or she nominates him or herself.

Open to all biomedical scientists within the UK, this award aims to showcase the diverse talents of those at the very top of their game.

8



IBMS award for Inspiring the biomedical workforce of the future

Sponsored by Institute of Biomedical Science

All those who play a part in inspiring biomedical scientists and biomedical support staff (clinical managers, department managers, educational supervisors and HR managers) are invited to nominate individuals or teams for this award. Our aim is to recognise and reward people committed to inspiring the next generation of biomedical scientists. We want to showcase the essential contribution that biomedical scientists make to attracting and developing a workforce which displays the behaviours and values that are needed to deliver professional care.

Awards open to AHPs only...

9



PHE and FPH award for contributions to public health

Sponsored by Public Health England & Faculty of Public Health

We seek to recognise allied health professionals who have demonstrated leadership and partnership working to deliver effective health improvement interventions at scale or with the potential to be used at scale.

11



The Scottish Government's award for improving quality: measuring and demonstrating impact

Sponsored by the Scottish Government

This award seeks to recognise AHPs who have transformed a service or services and in doing so can demonstrate an improved patient and staff experience. You need therefore to have had time to evaluate the innovation fully and to have modified the service appropriately. You should also be able to demonstrate that the transformed service is delivered in a way that improves the quality of patient care and must prove what you have achieved is sustainable.

13



Chroma award for Realising potential through creativity

Sponsored by Chroma

This award aims to find and showcase AHPs in England, working in the NHS, local government, the independent or third sectors, who use creative approaches, innovative ways of delivery, collaborative partnerships and cross-modal ways of working to engage patients in their own care and recovery. The award seeks to champion collaborative, compassionate and innovative AHPs, including arts therapists who exemplify these therapeutic approaches.

Entries must be submitted online via the website forms - go to AHPandHSAwards.co.uk and follow the **ENTER NOW** links

10



Northern Ireland award for Maximising resources for success

Sponsored by Department of Health (Northern Ireland)

This award recognises the crucial role of AHP leadership in driving forward service redesign to ensure safe, sustainable, and effective quality services provided in the right place at the right time by the right people. Health and social care services should place the individual at the centre by promoting better outcomes for service users, carers and their family. Outcomes and quality evidence should shape services to deliver the best outcomes for service users based on prevention initiatives, earlier interventions, and on promoting health and well-being.

12

theguardian

The Guardian award for innovation in mental health services

Sponsored by The Guardian

This award, introduced last year, attracting a record number of entries from AHPs working with people who have mental health problems. We particularly welcomed the unconventional partnerships, the different settings and the creative approaches that AHPs demonstrated in their entries. This year, we invite more of the same – and different!

14



The Macmillan award for Leadership and innovation in cancer rehabilitation

Sponsored by Macmillan Cancer Support

This award aims to recognise the importance of cancer rehabilitation at all stages of a patient's journey from diagnosis through to end of life care. Rehabilitation is aimed at maximising and optimising the patients physical, psychological and economic functioning while ensuring their dignity. AHPs play a major part in making this happen and we want to hear from you about your work.

Overall winner

The overall winner is chosen from the category winners

EVENT ITINERARY

- 9:00am** **Doors Open, Registration, Coffee & Pastries**
- Morning Session 1 - Cancer Diagnostics**
Chair: Prof Geoff Bellingan - *Medical Director for Surgery & Cancer Board, UCLH*
- 9.30am** **Introduction to the Day**
Prof. Michael Patton - *Professor of Medical Genetics, Medical Director, TDL/HSL*
- 9.40am** **Update on HSL Pathology**
Mr David Byrne - *CEO, Health Services Laboratories*
- 10.00am** **Future Directions in the Prevention of Cervical Cancer**
Mr Adam Rosenthal - *Consultant Gynaecologist, UCLH*
- 10.30am** **Advances in the Diagnosis & Management of Lympho-Proliferative Disease**
Dr Chris McNamara - *Consultant Haematologist, UCLH*
- 11.00am** **Coffee Break & Posters**
- Morning Session 2 - Infection & Immunity**
Chair: Dr Robin Smith - *Clinical Lead for Infection Sciences, HSL/Royal Free*
- 11.35am** **Why is CMV a Candidate for Elimination and then Eradication?**
Prof. Paul Griffiths - *UCL Medical School, Royal Free Campus*
- 12.05pm** **Getting More Out of TB Laboratory Diagnosis: Predicting Treatment Outcome**
Prof. Tim McHugh - *Professor of Medical Microbiology & Director, UCL Centre for Clinical Microbiology*
- 12.35pm** **The Delivery of a Sexual Health Service**
Dr Simon Edwards - *Clinical Director for Sexual Health Services, CNWL*
- 1:00pm** **Lunch & Posters**
- Afternoon Session 1 - Training within HSL**
Chair: Prof. Michael Patton - *Professor of Medical Genetics, Medical Director, TDL/HSL*
- 2.00pm** **Training Programs for Scientific Staff**
Miss Wendy Leversuch - *Head of Scientific Training, HSL*
- 2:15pm** **Support for Medical Training**
Dr Keith Gomez - *Head of Medical Training, HSL*
- 2.30pm** **Completing the Training Portfolio & Beyond**
Miss Orine Musonda - *Senior Biomedical Scientist*
- 2.45pm** **Undertaking a Master's Degree Part Time**
Dr Tony Madgwick - *Principal Lecturer in Cellular Pathology, University of Westminster*
- 3.10pm** **Coffee Break & Posters**
- Afternoon Session 2 - Translation Research & Awards**
Prof. Stephen Powis - *Medical Director, Royal Free*
- 3.40pm** **The Importance of Research in Medicine: A Personal Perspective**
Prof. Michael Patton - *Professor of Medical Genetics, Medical Director, TDL/HSL*
- 4.10pm** **Selected Presentations from HSL Staff**
- 4.40pm** **Closing Remarks**
Prof. Michael Patton - *Professor of Medical Genetics, Medical Director, TDL/HSL*
- 4.45pm** **Meeting Close**